4552 — JCR Pharmaceuticals Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapNeutral

Annual income statement for JCR Pharmaceuticals Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Tanshin
Standards:	JAS	JAS	JAS	JAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	30,085	51,082	34,343	42,871	33,072
Cost of Revenue
Gross Profit	22,273	40,621	25,457	31,251	21,739
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	21,646	32,255	29,388	35,340	38,848
Operating Profit	8,439	18,827	4,955	7,531	-5,776
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	8,653	19,404	5,412	7,244	-6,414
Provision for Income Taxes
Net Income After Taxes	6,889	14,518	3,787	5,537	-4,696
Minority Interest
Net Income Before Extraordinary Items
Net Income	6,893	14,508	3,773	5,509	-4,759
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	6,892	14,507	3,772	5,507	-4,759
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	54.5	123	30.4	44	-44
Dividends per Share
Special Dividends per Share